BioCentury | May 14, 2020
Deals

With Northern Biologics deal, Boehringer adds pair of hot topics to its immuno-oncology basket

...and other payments. The Northern L.P parent company retains MSC-1, a Phase I antibody against LIF...
...possible development paths for the retained MSC-1 program, including a separate deal. Targets LIF - Leukemia inhibitory factor...
BioCentury | Oct 7, 2019

Bispecific cytokine fusion for Type II diabetes

...II diabetes. The chimeric cytokine is based on IL-6, with a portion replaced by CTNF's LIF...
...receptor binding site and fused to an IgG Fc domain. The resulting protein binds CD126, LIF...
...neurotrophic factor (CNTF); interleukin-6 (IL-6); interleukin-6 (IL-6) receptor (CD126); interleukin-6 signal transducer (IL-6ST; gp130; CD130); leukemia inhibitory factor (LIF) receptor...
BioCentury | Aug 8, 2019
Distillery Therapeutics

LIF-expressing myeloid cells for DMD

...DISEASE CATEGORY: Musculoskeletal INDICATION: Muscular dystrophy LIF-expressing myeloid cells could help treat Duchenne muscular dystrophy (DMD...
...dystrophy (DMD). Bone-marrow derived macrophages, which infiltrate dystrophic muscle tissue, isolated from mice overexpressing human LIF...
...markers than cells from wild-type mice. In a mouse model of DMD, expression of human LIF...
BioCentury | Aug 8, 2019
Distillery Therapeutics

LIF inhibition sensitizes pancreatic cancer to chemotherapy

...DISEASE CATEGORY: Cancer INDICATION: Pancreatic cancer Inhibiting LIF could sensitize KRAS-driven pancreatic cancer to chemotherapy. LIF...
...a cell line expressing wild-type KRAS. In a mouse PDAC cell line, shRNA knockdown of LIF...
...has MSC-1, a humanized antibody against LIF, in Phase I testing for solid tumors. TARGET/MARKER/PATHWAY: Leukemia inhibitory factor (LIF)...
BioCentury | Apr 17, 2019
Preclinical News

Salk study unveils LIF's mechanism in form of pancreatic cancer

...started a Phase I trial of its anti-LIF mAb MSC-1 in solid tumors last year. LIF...
...LIF from Salk. Celgene Corp. (NASDAQ:CELG) has an option to acquire MSC-1. Targets: LIF - leukemia inhibitory factor...
...Corp. (NASDAQ:CELG) has an option to acquire MSC-1. Targets: LIF - leukemia inhibitory factor; LIFR (CD118) - leukemia inhibitory factor receptor...
BioCentury | Oct 31, 2018
Distillery Therapeutics

Ophthalmic disease

...a LIF-based fusion protein that could help treat blindness. The fusion protein consists of human LIF...
...of blindness. Allegis Pharmaceuticals LLC markets Primsol trimethoprim to treat urinary tract infections (UTI). TARGET/MARKER/PATHWAY: Leukemia inhibitory factor (LIF)...
...University of Florida, Gainesville, Fla. email: jash@ufl.edu Jaime De Leon Primsol (Brand), trimethoprim (Generic), Primsol (Informal) University of Florida Leukemia inhibitory factor (LIF) Blindness...
BioCentury | Jan 27, 2018
Strategy

Jump-starting growth

...suppressor cells (MDSCs) Reduce immunosuppression to enhance activity of CAR T cells MSC-1 Antibody against leukemia inhibitory factor (LIF)...
BioCentury | Nov 9, 2017
Company News

Vickers to helm Northern Biologics

...into the clinic for solid tumors early next year. MSC-1 is a humanized mAb targeting leukemia inhibitory factor (LIF)...
BioCentury | Oct 27, 2017
Preclinical News

Syros, UCSD team identifies pancreatic cancer targets

...suggested highly elevated expressions of leukemia inhibitory factor (LIF) in pancreatic tumors. In mouse models, data suggested inhibiting LIF...
...inhibited tumor growth and prolonged survival. Syros spokesperson Naomi Aoki told BioCentury the research identified LIF...
...potential targets. Northern Biologics Inc. (Toronto, Ontario) is developing MSC-1 , a humanized antibody targeting LIF...
BioCentury | Oct 26, 2017
Tools & Techniques

Ripe for enhancement

...a professor at the University of California San Diego, it identified targets related to IL-10, leukemia inhibitory factor (LIF)...
...CDK7 - Cyclin dependent kinase 7 HDAC - Histone deacetylase IL-10 - Interleukin-10 LIF - Leukemia inhibitory factor...
Items per page:
1 - 10 of 51